CAMP4 Therapeutics (NASDAQ:CAMP) Insider Yuri Maricich Acquires 6,551 Shares

CAMP4 Therapeutics Corporation (NASDAQ:CAMP) insider Yuri Maricich purchased 6,551 shares of the company’s stock in a transaction on Monday, August 3rd. The stock was purchased at an average cost of $1.65 per share, for a total transaction of $10,809.15. Following the purchase, the insider directly owned 12,611 shares in the company, valued at approximately $20,808.15. This trade represents a 108.10% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

CAMP4 Therapeutics Price Performance

CAMP stock opened at $4.01 on Thursday. The stock has a market capitalization of $208.24 million, a P/E ratio of -1.70 and a beta of 0.22. The business has a 50-day moving average of $4.02 and a 200-day moving average of $4.31. CAMP4 Therapeutics Corporation has a fifty-two week low of $1.32 and a fifty-two week high of $7.75.

CAMP4 Therapeutics (NASDAQ:CAMP) last posted its quarterly earnings data on Thursday, May 7th. The Wireless communications provider reported ($0.32) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.11). The firm had revenue of $1.29 million for the quarter. CAMP4 Therapeutics had a negative return on equity of 194.74% and a negative net margin of 2,193.72%. Equities analysts expect that CAMP4 Therapeutics Corporation will post -0.84 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in CAMP. China Universal Asset Management Co. Ltd. bought a new stake in CAMP4 Therapeutics in the 4th quarter valued at $61,000. Jefferies Financial Group Inc. bought a new position in CAMP4 Therapeutics during the fourth quarter worth $70,000. Bank of America Corp DE acquired a new stake in shares of CAMP4 Therapeutics during the 4th quarter worth about $86,000. OMERS ADMINISTRATION Corp bought a new stake in shares of CAMP4 Therapeutics during the 4th quarter worth about $115,000. Finally, Goldman Sachs Group Inc. acquired a new position in CAMP4 Therapeutics in the 4th quarter valued at about $115,000.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on the stock. Chardan Capital set a $6.50 target price on shares of CAMP4 Therapeutics and gave the stock a “buy” rating in a report on Wednesday, June 10th. Zacks Research cut CAMP4 Therapeutics from a “hold” rating to a “strong sell” rating in a report on Wednesday, July 15th. Weiss Ratings cut CAMP4 Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, May 21st. Rodman & Renshaw initiated coverage on CAMP4 Therapeutics in a research report on Tuesday, April 14th. They set a “buy” rating and a $7.00 price target on the stock. Finally, JPMorgan Chase & Co. raised CAMP4 Therapeutics from a “neutral” rating to an “overweight” rating and increased their price objective for the company from $5.00 to $9.00 in a report on Tuesday, June 16th. Seven analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, CAMP4 Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $8.36.

CAMP4 Therapeutics News Summary

Here are the key news stories impacting CAMP4 Therapeutics this week:

• Positive Sentiment: Insider buying signals management confidence. CEO Josh Mandel-Brehm, CFO Kelly Gold, Director Richard A. Young and insider Yuri Maricich collectively purchased 36,031 shares at $1.65 per share. The purchases increased their respective holdings, although the transactions were relatively small in dollar terms. Insider purchase filings
• Positive Sentiment: CAMP4 raised approximately $50.1 million in the second closing of its private placement. The proceeds are intended to fund CMP-002, the company’s lead antisense oligonucleotide candidate, and its early-stage pipeline. The financing included participation from institutional investors such as Janus Henderson, Balyasny Asset Management, Vivo Capital and 5AM Ventures. CAMP4 private placement announcement
• Positive Sentiment: CMP-002 moved closer to human testing. CAMP4 said it received Australian regulatory and ethics clearance to begin a Phase 1/2 trial for SYNGAP1-related disorder, a rare neurological disease with no approved disease-modifying therapies. Preclinical testing showed increased SYNGAP1 protein expression and improvements in disease-relevant animal models. CAMP4 financing and CMP-002 update
• Negative Sentiment: The financing is materially dilutive. CAMP4 issued more than 10.7 million common shares and approximately 21.9 million pre-funded warrants at roughly $1.53 per share-equivalent, potentially expanding the share count significantly. The discounted issuance may weigh on the stock even though it provides additional operating runway.
• Neutral Sentiment: Clinical execution remains the key catalyst and risk. The Phase 1/2 trial could provide important validation, but CMP-002 remains investigational and preclinical results do not guarantee safety or efficacy in humans.

About CAMP4 Therapeutics

CalAmp Corp., a connected intelligence company, provides leverages a data-driven solutions ecosystem to people and organizations in the United States, Europe, the Middle East, Africa, Latin America, the Asia-Pacific, and internationally. The company operates in two segments, Software & Subscription Services and Telematics Products. It provides CalAmp Telematics Cloud platform, such as cloud-based application enablement and telematics service platforms that facilitate integration of its own applications, as well as those of third parties, through open application programming interfaces; and software as a service application, as well as provides tracking and monitoring services within fleet management, supply chain integrity, and international vehicle location.